Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 383

1.

Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group.

McCloskey RV, Straube RC, Sanders C, Smith SM, Smith CR.

Ann Intern Med. 1994 Jul 1;121(1):1-5.

PMID:
8198341
2.

Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group.

Ziegler EJ, Fisher CJ Jr, Sprung CL, Straube RC, Sadoff JC, Foulke GE, Wortel CH, Fink MP, Dellinger RP, Teng NN, et al.

N Engl J Med. 1991 Feb 14;324(7):429-36.

3.
4.

Human monoclonal antibody against endotoxin.

Zarowitz BJ.

DICP. 1991 Jul-Aug;25(7-8):778-83. Review.

PMID:
1949939
6.

An evaluation of the hemodynamic effects of HA-1A human monoclonal antibody.

Kett DH, Quartin AA, Sprung CL, Fisher CJ Jr, Peña MA, Heard SO, Zimmerman JL, Albertson TE, Panacek EA, Eidelman LA, et al.

Crit Care Med. 1994 Aug;22(8):1227-34.

PMID:
8045141
7.

A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group.

Bone RC, Balk RA, Fein AM, Perl TM, Wenzel RP, Reines HD, Quenzer RW, Iberti TJ, Macintyre N, Schein RM.

Crit Care Med. 1995 Jun;23(6):994-1006. Erratum in: Crit Care Med 1995 Sep;23(9):1616.

PMID:
7774238
10.

Gram-negative sepsis, the sepsis syndrome, and the role of antiendotoxin monoclonal antibodies.

Barriere SL, Guglielmo BJ.

Clin Pharm. 1992 Mar;11(3):223-35. Review.

PMID:
1611812
11.
12.

Effectiveness of a human monoclonal anti-endotoxin antibody (HA-1A) in gram-negative sepsis: relationship to endotoxin and cytokine levels.

Wortel CH, von der Möhlen MA, van Deventer SJ, Sprung CL, Jastremski M, Lubbers MJ, Smith CR, Allen IE, ten Cate JW.

J Infect Dis. 1992 Dec;166(6):1367-74.

PMID:
1431255
13.

Projected impact of monoclonal anti-endotoxin antibody therapy.

Bates DW, Lee TH.

Arch Intern Med. 1994 Jun 13;154(11):1241-9.

PMID:
8203991
14.

[Immunotherapy using the anti-endotoxin antibody HA-1A (Centoxin) in patients with sepsis syndrome; fair results following protocol selection of patients].

Costongs LG, Speelman P, van Lieshout JJ, van Deventer SJ, Lubbers MJ, Schipper HG.

Ned Tijdschr Geneeskd. 1993 Feb 13;137(7):355-60. Dutch.

PMID:
8437634
16.
17.

Multicenter evaluation of a human monoclonal antibody to Enterobacteriaceae common antigen in patients with Gram-negative sepsis.

Albertson TE, Panacek EA, MacArthur RD, Johnson SB, Benjamin E, Matuschak GM, Zaloga G, Maki D, Silverstein J, Tobias JK, Haenftling K, Black G, Cowens JW; MAB-T88 Sepsis Study Group.

Crit Care Med. 2003 Feb;31(2):419-27.

PMID:
12576946
18.

Observations using antiendotoxin antibody (E5) as adjuvant therapy in humans with suspected, serious, gram-negative sepsis.

Greenberg RN, Wilson KM, Kunz AY, Wedel NI, Gorelick KJ.

Crit Care Med. 1992 Jun;20(6):730-5.

PMID:
1597023
19.

Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients.

Abraham E, Laterre PF, Garbino J, Pingleton S, Butler T, Dugernier T, Margolis B, Kudsk K, Zimmerli W, Anderson P, Reynaert M, Lew D, Lesslauer W, Passe S, Cooper P, Burdeska A, Modi M, Leighton A, Salgo M, Van der Auwera P; Lenercept Study Group.

Crit Care Med. 2001 Mar;29(3):503-10.

PMID:
11373411
20.

Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group.

Opal SM, Fisher CJ Jr, Dhainaut JF, Vincent JL, Brase R, Lowry SF, Sadoff JC, Slotman GJ, Levy H, Balk RA, Shelly MP, Pribble JP, LaBrecque JF, Lookabaugh J, Donovan H, Dubin H, Baughman R, Norman J, DeMaria E, Matzel K, Abraham E, Seneff M.

Crit Care Med. 1997 Jul;25(7):1115-24.

PMID:
9233735

Supplemental Content

Support Center